Curatis identifies potential drug candidates in indications with high unmet medical need via its extensive network within the scientific and medical community, as well as within the biotech/pharmaceutical industry. Curatis invests a significant portion of its revenues and resources in its development activities.

The current pipeline is a balance of preclinical and clinical compounds with clinically validated targets.

*Curatis has spun off its two phase II development projects C-MOH-01 for the treatment of medication overuse headache and C-AM-01 for the prevention of severe migraine with aura into CapiThera Ltd (www.capithera.com).

**Amyotrophic lateral sclerosis